Drug Channels
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/

Drug Channels's articles

  1. Trends & External Forces

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. We have identified nearly 1,800 dispensing sites with specialty pharmacy accreditation—about 40% of which are owned by hospitals, physician practices, and other healthcare providers. Alas, specialty pharmacies owned by the three largest […]
2 min read
0
  1. Data & Insights

How Patient Engagement Can Reduce Brand Launch Risks

Today’s guest post comes from Jessica Lens, Chief Patient Experience Officer at CareMetx. Jessica discusses the challenges of patient nonadherence. She then outlines how manufacturers can build adherence into their patient services program to increase patient engagement. To learn more about enhancing patient engagement and adherence, download CareMetx’s new report: Driving Brand Success: Minimize Risk and […]
2 min read
0
  1. Department: HBC

The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead

Three is still the magic number for pharmacy benefit managers (PBMs). For 2023, nearly 80% of all equivalent prescription claims were processed by three companies: the Caremark business of CVS Health, the Express Scripts business of Cigna, and the Optum Rx business of UnitedHealth Group. Read on for Drug Channels Institute’s (DCI’s) latest market share […]
2 min read
0
  1. Trends & External Forces

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

I am pleased to announce the inaugural Drug Channels Leadership Forum! This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial […]
3 min read
0
  1. Trends & External Forces

Tales of the Unsurprised: U.S. Brand-Name Drug Prices Fell for an Unprecedented Sixth Consecutive Year—And Will Fall Further in 2024 (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. One important update: In the article below, I suggested that the IRA will make high-list/high-rebate products less attractive to Medicare plans. But this appears not be accurate, as I explain in Surprise! […]
3 min read
0
  1. Trends & External Forces

Vertical Integration Lessons: The Economics and Strategies of Hospital-Owned Specialty Pharmacies (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For updated data on hospital-owned specialty pharmacies, see Chapter 3 of DCI’s new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Click here to see the original post from November […]
2 min read
0
  1. Channel: Drug

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For more on acquisition cost reimbursement for pharmacies, see Sections 8.4. and 12.3.4. of our new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Click here to see the original […]
3 min read
0
  1. Trends & External Forces

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Click here to see the original post from December 2023. Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a […]
2 min read
0
  1. Data & Insights

Navigating Market Access Challenges in Life Sciences Commercialization

Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis. Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, March 2024: My $0.02 of CarelonRx/Kroger & CVS, Provider-Owned Pharmacies, Shady AFPs, 340B Deception, and Lilly’s GLP-1 Ad

It’s finally spring in Philadelphia, home of Drug Channels. Along with sunshine and fine weather, the vernal equinox has ushered in a crop of new and noteworthy stories: What the CarelonRx/Kroger specialty pharmacy deal means for CVS Health Provider-owned specialty pharmacies expand in Medicare Payers are not keen on shady alternative funding programs (AFP) Hospitals’ […]
2 min read
0
  1. Shopper & Customer

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Today’s guest post comes from Adam Stotts, SVP of Customer Success at AssistRx. Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. To learn about AssistRx’s digital intake solutions, download […]
2 min read
0
  1. Trends & External Forces

Mark Cuban: Five Ways that Big PBMs Hurt U.S. Healthcare–And How We Can Fix It

Today’s guest post comes from Mark Cuban, co-founder of the Mark Cuban Cost Plus Drug Company A few weeks ago, Mark participated in the White House Roundtable on Lowering Healthcare Costs and Bringing Transparency to Prescription Drug Middlemen. I found Mark’s comments to be intriguing and highly provocative, so I invited him to publish an […]
2 min read
0